Human TrkA/NTRK1 (aa 194-413, His Tag) recombinant protein

Human TrkA/NTRK1 (aa 194-413, His Tag) recombinant protein

• DataSheet
• Material Safety Data Sheets (MSDS)

TRKA is a member of the neurotrophic tyrosine kinase receptor (NTKR) family. It is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed. Isoform TrkA-I is found in most non-neuronal tissues. Isoform TrkA-II is primarily expressed in neuronal cells. TrkA-III is specifically expressed by pluripotent neural stem and neural crest progenitors. The presence of NTRK1 leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in TRKA gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation and cancer. It was originally identified as an oncogene as it is commonly mutated in cancers, particularly colon and thyroid carcinomas. TRKA is required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF). Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1. NTRK1 has a crucial role in the development and function of the nociceptive reception system as well as establishment of thermal regulation via sweating. It also activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway. Defects in NTRK1 are a cause of congenital insensitivity to pain with anhidrosis and thyroid papillary carcinoma.

High affinity nerve growth factor receptor

TRKA; TRK-A; P140-TRKA; C80751; NTRK1; MTC; TKR; DKFZP781I14186; TRK1; TRK

P04629

NTRK1; MTC; TRK; TRKA

Human Cells

A DNA sequence encoding the amino acid sequence (Pro 194-Glu 413) of human NTRK1 (NP_002520.2), corresponding to the Ig-like C2-type 1 & 2 domains, was expressed and purified, with a N-terminal polyhistidine tag.

Human

The recombinant human NTRK1 Ig-like C2-type 1 & 2 domains (aa 194-413) consists of 239 amino acids and has a predicted molecular mass of 26 kDa. As a result of glycosylation, it migrates as an approximately 45-50 kDa band in SDS-PAGE under reducing conditions.

> 95 % as determined by SDS-PAGE

Measured by its ability to inhibit NGF-induced proliferation of TF1 human erythroleukemic cells.
The ED₅₀ for this effect is typically 0.5-4 μg/ml in the presence of 10 ng/mL of human NGF.